Overview

Welcome to Dwaey, specifically on MOUNJARO 5m 5ml Solution for Injection page.
This medicine contains an important and useful components, as it consists of Tirzepatide.
MOUNJARO 5m 5ml is available in the market in concentration 5mg 0.5ml and in the form of Solution for Injection.

ELI LILLY AND COMPANY is the producer of MOUNJARO 5m 5ml and it is imported from USA, The most popular alternatives of MOUNJARO 5m 5ml are listed downward .

Mode Of Action & Indication

Mounjaro (terzepatide) is an injectable GLP-1 receptor agonist used for the treatment of type 2 diabetes and obesity. It works by mimicking the action of two hormones that are important in the regulation of blood sugar and appetite: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). GLP-1 and GIP are released by the gut in response to food intake and stimulate the release of insulin from the pancreas, which helps to lower blood sugar levels. They also slow down the emptying of the stomach, which can help to reduce appetite and promote feelings of fullness. Mounjaro activates the GLP-1 and GIP receptors in the body, which leads to increased insulin secretion and reduced glucagon secretion (a hormone that raises blood sugar levels), thereby lowering blood sugar levels. It also slows down the emptying of the stomach, which can help to reduce appetite and promote weight loss. In addition to its effects on blood sugar and appetite, Mounjaro may also have other beneficial effects, such as improving cardiovascular risk factors and reducing liver fat. Overall, Mounjaro is a promising new treatment option for patients with type 2 diabetes and obesity, and may offer significant benefits beyond just blood sugar control.

Indication

• Treatment of type 2 diabetes: Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
• Treatment of obesity: Tirzepatide is indicated as an adjunct to diet and exercise for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obese) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity
• It is important to note that Tirzepatide is not recommended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should also not use Tirzepatide
• Furthermore Tirzepatide should not be used in combination with other GLP-1 receptor agonists or insulin as this may increase the risk of hypoglycemia. Patients should be monitored regularly for signs and symptoms of pancreatitis hypersensitivity reactions and other adverse effects while taking Tirzepatide.

Precaution

Mounjaro (terzepatide) is a GLP-1 receptor agonist used for the treatment of type 2 diabetes and obesity. There are several precautions that should be taken into consideration before using Mounjaro: Hypoglycemia: Mounjaro can cause hypoglycemia (low blood sugar), particularly when used in combination with other medications that lower blood sugar. Patients should be advised to monitor their blood sugar levels regularly and to be aware of the symptoms of hypoglycemia. Pancreatitis: Mounjaro may increase the risk of pancreatitis, a serious condition that can cause severe abdominal pain, nausea, and vomiting. Patients should be advised to seek medical attention immediately if they experience these symptoms. Renal impairment: Mounjaro may worsen renal function, particularly in patients with pre-existing kidney disease. Patients with renal impairment should be monitored closely while using Mounjaro. Gastrointestinal adverse events: Mounjaro may cause gastrointestinal adverse events, such as nausea, vomiting, diarrhea, and constipation. Patients should be advised to contact their healthcare provider if they experience these symptoms. Thyroid C-cell tumors: Mounjaro may increase the risk of thyroid C-cell tumors. Patients with a family history of MTC or MEN 2 should be screened for MTC before starting treatment with Mounjaro. Injection site reactions: Mounjaro is administered by injection and may cause injection site reactions, such as redness, swelling, and pain. Patients should be advised to rotate injection sites and to seek medical attention if they experience persistent injection site reactions. Immunosuppression: Mounjaro may decrease the immune response to certain infections. Patients should be advised to inform their healthcare provider if they develop any signs of infection while using Mounjaro. It is important to discuss these precautions with your healthcare provider before starting treatment with Mounjaro. They can help determine if this medication is safe and appropriate for you and can provide guidance on how to minimize the risk of adverse events.

Side Effects

• Mounjaro (terzepatide) is a new GLP-1 receptor agonist that is used for the treatment of type 2 diabetes and obesity. As with any medication- Mounjaro may cause side effects in some patients. Common side effects of Mounjaro include nausea
• vomiting
• diarrhea
• constipation
• abdominal pain
• loss of appetite
• and headache. These side effects are usually mild to moderate and tend to improve over time as the body adjusts to the medication. In addition Mounjaro may cause more serious side effects in some patients. These can include
• Hypoglycemia (low blood sugar): This can occur if Mounjaro is used in combination with other medications that lower blood sugar
• such as insulin or sulfonylureas. Symptoms of hypoglycemia include sweating
• shakiness
• dizziness
• confusion
• and blurred vision
• Pancreatitis: This is a rare but serious side effect that can occur with the use of GLP-1 receptor agonists. Symptoms of pancreatitis include severe abdominal pain that may radiate to the back nausea and vomiting
• Kidney problems: Mounjaro may cause worsening of kidney function particularly in patients with pre-existing kidney disease
• Allergic reactions: Some patients may develop an allergic reaction to Mounjaro
• which can cause symptoms such as hives itching and difficulty breathing
• If you experience any of these side effects or any other unusual symptoms while taking Mounjaro it is important to contact your healthcare provider immediately. They can help determine the cause of your symptoms and adjust your treatment plan if necessary.

Contra indication

Mounjaro (terzepatide) is a GLP-1 receptor agonist used for the treatment of type 2 diabetes and obesity. There are several contraindications to the use of Mounjaro, which include: History of medullary thyroid carcinoma (MTC): Mounjaro should not be used in patients with a history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Hypersensitivity to terzepatide or any of its components: Patients who have had an allergic reaction to terzepatide or any of its components should not use Mounjaro. Pancreatitis: Mounjaro should not be used in patients with a history of pancreatitis or in patients with a history of chronic pancreatitis. Type 1 diabetes: Mounjaro is not recommended for use in patients with type 1 diabetes. Diabetic ketoacidosis (DKA): Mounjaro is not recommended for the treatment of DKA. Severe gastrointestinal disease: Mounjaro should not be used in patients with severe gastrointestinal disease, such as gastroparesis or inflammatory bowel disease. Pregnancy and breastfeeding: There is limited data on the safety of Mounjaro in pregnancy and breastfeeding, and it should be used only if the potential benefits outweigh the potential risks. If you have any of these conditions or are allergic to any of the components of Mounjaro, it is important to inform your healthcare provider before starting treatment with this medication. They can help determine if Mounjaro is safe and appropriate for you and may recommend alternative treatments if necessary.

Pregnancy and lactation

Pregnancy category: